Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech vs. Shorts -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (422)	4/20/2004 1:29:10 PM
From: scaram(o)uche	Respond to of 427

>> the market cap is tiny compared to peers << That was going too far. "Modest", not "tiny". And "compared" implies "relative", a means of biotech valuation that often bites. One year. The traditional biotech investor's dream is that one of the INDs takes up enough of the research premium (yahoo's enterprise value?) such that -- in a year -- flurbie is a freebie. Today's release put the phase II trial on radar for lotsa business development and licensing professionals.